Design and outcome-model estimability in doubly robust survival analysis: a breast cancer reanalysis

Doubly robust survival estimators require nuisance models that the available information can support. We examine design and estimator dependence in TCGA breast cancer data. Treatment indicators disagree for 337 of 1076 patients; 67.4% have unobserved five-year binary outcomes; and receptor imputation expands the triple-negative subgroup from 156 directly measured patients to 226. We compare chemotherapy initiation by day 90 with non-initiation, using adjusted restricted mean survival time (RMST) over the next 1095 days. Weighting-only estimates are 55 days (95% bootstrap interval: -24, 133) in

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.